Glucagon
As of the edition of 20 October 2026, Glucagon is a protein: marketed, first approved in 1965 (CH); acts on GCGR; no US protection of its own is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2020
- Kind
- Protein
- Brand name
- Glucagen
- First approved
- 6 May 1965 (CH)
- Approvals on record
- 20 in 5 regions
- Holder of the most recent approval
- Xeris Pharmaceuticals; 8 holders in all
- Registered trials
- 84, 6 stopped early
- Disease areas
- Nutrition and metabolism; Hormones; Immune system; Digestive system; Inherited and neonatal; Pregnancy and women's health
US protection
No US protection of its own is listed.
The FDA registers list no drug-substance patent or exclusivity of its own that counts for this drug.
Amphastar Pharmaceuticals holds a later exclusivity on its own new formulation or combination product, ending 2028; it does not protect the original drug.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route B because of this drug.
Companies on route B for this drug
In the product2 companies are on route B because of Glucagon.
See the 2 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| GCGR | Glucagon receptor | P47871 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 20 | 10 | 5 | 1 |
| Phase 1 | 25 | 21 | 2 | 2 |
| Phase 2 | 17 | 14 | 1 | 2 |
| Phase 3 | 12 | 11 | 0 | 0 |
| Phase 4 | 10 | 5 | 2 | 1 |
| All trials | 84 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Novo Nordisk | Applicant and Lead sponsor of trials | 1965 to now |
| Eli Lilly | Applicant and Lead sponsor of trials | 2011 to now |
| Fresenius Kabi | Later holder and Lead sponsor of trials | 2013 to now |
| Xeris Pharmaceuticals | Later holder and Lead sponsor of trials | 2014 to now |
| Amphastar France Pharmaceuticals | Applicant | 2019 to now |
| Cortendo | Later holder | 2021 to now |
| Amphastar Pharmaceuticals | Acquired holder | 2023 to now |